Physician profile
Matthew G Meyer
NPI 1467499459
$400.25
in general payments reported to CMS, 2019-2025
12 companies · $19.89 in 2025
The $19.89 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $18.78 · 2023: $22.06 · 2024: $39.09 · 2025: $19.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $181.90 | 2019 | |
| Glaxosmithkline, LLC. | $49.87 | 2019-2025 | Bexsero |
| Teva Pharmaceuticals USA, INC. | $25.55 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.06 | 2023 | |
| Ironshore Pharmaceuticals INC. | $21.15 | 2019 | |
| Cranial Technologies, INC | $18.78 | 2020 | |
| Merz North America, INC. | $17.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.13 | 2019 | |
| Mission Pharmacal Company | $12.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.25 | 2019 | |
| Merck Sharp & Dohme LLC | $11.02 | 2019 | |
| Adlon Therapeutics L.P. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.